# EDGAR Filing Document

**Accession Number:** 0001778016
**File Stem:** 0001193125-25-170884
**Filing Date:** 2025-8
**Character Count:** 2936
**Document Hash:** d516d609d022f0b9418404550dd01aa3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-170884.hdr.sgml**: 20250801

**ACCESSION NUMBER**: 0001193125-25-170884

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250801

**FILED AS OF DATE**: 20250801

**DATE AS OF CHANGE**: 20250801

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** I-Mab
- **CENTRAL INDEX KEY:** 0001778016
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39173
- **FILM NUMBER:** 251173542

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 400, 2440 RESEARCH BLVD
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** (301) 670 2800

**MAIL ADDRESS:**
- **STREET 1:** SUITE 400, 2440 RESEARCH BLVD
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the Month of August 2025** 

**Commission File Number: 001-39173** 

## I-MAB
**2440 Research Boulevard, Suite 400** 

**Rockville, MD 20850** 

**(Address of registrant's principal executive offices)** 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

------

**Cash Position** 

On August 1, 2025, I-Mab (the "Company") announced that it expects to report that it had cash and cash equivalents, and short-term investments of $165.6 million as of June 30, 2025.

The Company expects to report its full financial results for the three and six months ended June 30, 2025 later this quarter. The preliminary financial results described in this report have not been audited or reviewed by our auditors and are subject to adjustment based on the Company's completion of quarter-end financial close processes.

The information contained this Report on Form 6-K shall be deemed to be incorporated by reference into the Registrant's Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File Nos. 333-239871, 333-265684, 333-256603, and 333-279842) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **I-MAB** |
|  | (Registrant) |
| Date: August 1, 2025 | /s/ Joseph Skelton |
|  | Name: Joseph Skelton |
|  | Title: Chief Financial Officer |

---